Compare STRIDES PHARMA SCIENCE with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ALKEM LABORATORIES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ALKEM LABORATORIES STRIDES PHARMA SCIENCE/
ALKEM LABORATORIES
 
P/E (TTM) x 14.8 - - View Chart
P/BV x 0.9 6.6 13.2% View Chart
Dividend Yield % 0.6 0.7 85.2%  

Financials

 STRIDES PHARMA SCIENCE   ALKEM LABORATORIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ALKEM LABORATORIES
Mar-16
STRIDES PHARMA SCIENCE/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1471,589 72.2%   
Low Rs6421,232 52.1%   
Sales per share (Unadj.) Rs317.2417.5 76.0%  
Earnings per share (Unadj.) Rs7.856.3 13.9%  
Cash flow per share (Unadj.) Rs25.164.7 38.7%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.20.9 24.8%  
Book value per share (Unadj.) Rs274.3292.9 93.6%  
Shares outstanding (eoy) m89.50119.57 74.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.4 83.4%   
Avg P/E ratio x114.025.1 455.1%  
P/CF ratio (eoy) x35.721.8 163.8%  
Price / Book Value ratio x3.34.8 67.7%  
Dividend payout %25.522.6 113.0%   
Avg Mkt Cap Rs m80,058168,653 47.5%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,3419,171 47.3%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,39449,915 56.9%  
Other income Rs m9411,645 57.2%   
Total revenues Rs m29,33451,561 56.9%   
Gross profit Rs m3,9658,482 46.7%  
Depreciation Rs m1,5401,006 153.2%   
Interest Rs m1,962671 292.6%   
Profit before tax Rs m1,4038,451 16.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,606 6.1%   
Profit after tax Rs m7026,731 10.4%  
Gross profit margin %14.017.0 82.2%  
Effective tax rate %6.919.0 36.5%   
Net profit margin %2.513.5 18.3%  
BALANCE SHEET DATA
Current assets Rs m24,83627,062 91.8%   
Current liabilities Rs m18,99315,324 123.9%   
Net working cap to sales %20.623.5 87.5%  
Current ratio x1.31.8 74.0%  
Inventory Days Days7167 106.7%  
Debtors Days Days11341 274.7%  
Net fixed assets Rs m34,28912,610 271.9%   
Share capital Rs m895239 374.3%   
"Free" reserves Rs m23,65134,490 68.6%   
Net worth Rs m24,54635,027 70.1%   
Long term debt Rs m15,5131,212 1,280.4%   
Total assets Rs m65,43754,387 120.3%  
Interest coverage x1.713.6 12.6%   
Debt to equity ratio x0.60 1,827.1%  
Sales to assets ratio x0.40.9 47.3%   
Return on assets %4.113.6 29.9%  
Return on equity %2.919.2 14.9%  
Return on capital %6.924.9 27.7%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m15,6976,563 239.2%   
Fx outflow Rs m7353,012 24.4%   
Net fx Rs m14,9623,552 421.3%   
CASH FLOW
From Operations Rs m1,8717,259 25.8%  
From Investments Rs m5,8261,864 312.5%  
From Financial Activity Rs m-10,157-9,273 109.5%  
Net Cashflow Rs m-2,615-150 1,743.3%  

Share Holding

Indian Promoters % 27.7 66.9 41.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 33.1 114.2%  
FIIs % 8.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 0.0 -  
Shareholders   56,241 68,381 82.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS